Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study

NEW YORK, Nov. 13, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more than 50% of the expected 285 patients for its 90-day dose-ranging Pivotal Phase 2b clinical study of its oral insulin […]

Join our mailing list

Skip to content